EP0212428B1

EP0212428B1 - Dihydrobenzo/b /thiophenes and pharmaceutical compositions thereof useful as antifungals

Info

Publication number: EP0212428B1
Application number: EP86110821A
Authority: EP
Inventors: Dinanath Fakir Rane; Russell Edwin Pike
Original assignee: Schering Corp
Current assignee: Merck Sharp and Dohme LLC
Priority date: 1985-08-12
Filing date: 1986-08-05
Publication date: 1990-06-06
Anticipated expiration: 2006-08-05
Also published as: AR244224A1; DE3671748D1; FI95251B; KR900000673B1; ATE53390T1; IL79598A0; IE862104L; AU585381B2; HUT44784A; FI863168A0; AU6085486A; DK370886A; CN86105964A; CN1022105C; ES2001866A6; IE59028B1; NO171066C; US4731364A; HU209302B; GR862058B

Description

This invention relates to 2-alkyl-, 2-alkenyl and 2-alkynyl-2,3-dihydro-2-[1H-azolyl(C₁-C₂)alkyl]-benzo[b]thiophenes and related derivatives which exhibit antifungal activity, pharmaceutical compositions thereof and methods for their use in treating fungal infections in a host including warm-blooded animals such as humans.
Various antifungal 2,3-dihydro-2-(1H-imidazolylmethyl)benzo[b]thiophenes are known. For example U.S. Patent 4,431,816 discloses 3-hydroxy-2,3-dihydro-2-(1H-1-imidazolylmethyl)benzo[b]thiophenes and European Patent Application EP 54,233 discloses cis-6-chloro-3-allyloxy-2,3-dihydro-2-(l H-I-imidazolylmethyl)benzo[b]thiophene.
However, none of the references are directed to the 2-alkyl, 2-alkenyl or 2-alkynyl compounds of this invention.
The compounds of this invention are represented by the following formula I:
in racemic or optically active form, or a pharmaceutically acceptable salt thereof wherein

X is one or more groups selected independently from halogen, C_l-₆ alkyl, halo C₁-C₆ alkyl, cyano, nitro or substituted and unsubstituted phenyl, or substituted or unsubstituted phenyl C_l-₆ alkyl wherein the substituents comprise one to four of one or more groups selected from halogen, nitro, -NR₄R₅, C₂-8 alkanoyl, C_1-6 alkyl, and halo C_1-6 alkyl;
Y is substituted or unsubstituted imidazolyl or substituted or unsubstituted 1,2,4-triazolyl, said substituents being one to three of one or more groups selected independently from C₁_₆ alkyl or substituted and unsubstituted phenyl, or substituted or unsubstituted phenyl C₁_₆ alkyl wherein the substituents comprise one to four of one or more groups selected from halogen, nitro, ―NR₄R₅, C₂-₈ alkanoyl, C_i-₆ alkyl, and halo C₁_₆alkyl;
R₁ and R₂ are independently hydrogen, -CH₂NR₄R₅, ―NR₄R₅, -OR₄, -SR_S, C₁_₆ alkyl, C₂_₈ alkynyl, halogen, or substituted and unsubstituted phenyl, or substituted or unsubstituted phenyl C₁_₆ alkyl wherein the substituents comprise one to four of one or more groups selected from halogen, nitro, ―NR₄R5, C₂_₈ alkanoyl, C₁_₆ alkyl, and halo C₁_₆ alkyl or R₁ and R₂ together with the carbon atom to which they are attached form carbonyl, thiocarbonyl,

and R₆, R₇, R₈ and Rg are independently hydrogen, C_l-₆ alkyl; or substituted and unsubstituted phenyl, or substituted or unsubstituted phenyl C₁_₆ alkyl wherein the substituents comprise one to four of one or more groups selected from halogen, nitro, ―NR₄R₅, C₂-₈ alkanoyl, C₁_₆ alkyl, and halo C₁_₆ alkyl; or substituted or unsubstituted heterocyclyl, being a five- or six-membered ring system containing carbon and one to four hetero atoms selected from one or more of N, O, and S, said heterocyclyl substituents being halogen, C₁_₆ alkyl, C_2-8 alkanoyl, or substituted and unsubstituted phenyl, or substituted or unsubstituted phenyl C₁_₆ alkyl wherein the substituents comprise one to four of one or more groups selected from halogen, nitro, -NR₄R₅, C₂-₈ alkanoyl, C₁_₆ alkyl, and halo C₁_₆ alkyl;
R₄ and R₅ are independently hydrogen, C₁_₆ alkyl, N,N-diC₁_₆ alkyl carbamoyl, N,N-diC₁_₆ alkyl thiocarbamoyl, arylcarbonyl, or substituted or unsubstituted phenyl, or substituted or unsubstituted phenyl C₁_₆ alkyl wherein the substituents comprise one to four of one or more groups selected from halogen, nitro, ―NR₄R₅, C₂_₈ alkanoyl, C₁_₆ alkyl, and halo C₁_₆ alkyl, or R₄ and R₅ taken together with the nitrogen atom to which they are attached in -NR₄R₅ and -CH₂NR₄R₅ form substituted or unsubstituted heterocyclyl as defined above;
Z is 0, S or NR₅ where where R₅ is as defined previously;
m is 1, 2, 3 or 4; and
n is 1 or 2.

This invention also provides a pharmaceutical composition comprising an antifungally effective amount of a compound represented by formula I or a pharmaceutically acceptable acid salt thereof, together with a pharmaceutically acceptable carrier or diluent.
This invention further provides a method of treating susceptible fungal infections which comprises administering to a host, e.g., warm-blooded animals including humans, in need of such treatment an antifungally effective amount of a compound represented by formula I or a pharmaceutical composition comprising such a compound and a pharmaceutically acceptable carrier or diluent.
As used in the specification and claims, the term "halogen" means bromine, chlorine or fluorine with chlorine and fluorine being prefered; fluorine is most preferred. The term "(lower)alkyl" refers to straight and branched chain hydrocarbon groups of 1 to 6 carbon atoms, such as methyl, ethyl, n- and iso-propyl, n-, sec- and tert-butyl, n-, sec-, iso-, tert- and neo-pentyl, n-, sec-, iso- and tert-hexyl. The term "halo(lower)alkyl" refers to "(lower)alkyl" groups having at least one halogen substituent, e.g., -CH₂-CF₃, -CF₂-CH₃ as well as perhalo groups such as -CF=CF3 or -CF₃; trifluoromethyl is preferred. The term "(lower)alkanoyl" refers to straight and branched chain alkanoyl groups having 2 to 8 carbon atoms such as acetyl, propanoyl, butanoyl, 2-methylpropanoyl, 3-methylpropanoyl, pentanoyl, 2-methylbutanoyl, 3-methylbutanoyl, 4-methylbutanoyl, hexanoyl, 2-methylpentanoyl, 3-methylpentanoyl, 4-methylpentanoyl, 5-methylpentanoyl, heptanoyl, 2-methylheptanoyl, octanoyl, 2-ethylhexanoyl and the like. Acetyl is preferred.
The term "heterocyclyl" refers to five- and six-membered ring systems containing carbon and one to four heteroatoms chosen from N, O and S. Typical suitable heterocyclyls include morpholino, piperazino, pyrrolidino, piperidino, imidazolyl, 1,2,4-triazolyl, furanyl, thienyl, thiadiazolyls (especially 1,2,3-thiadiazol-4-yl and 1,2,3-thiadiazol-5-yl), thiomorpholino, and pyridyls. The heterocyclyl may be attached via a carbon atom, e.g., N-methylpiperidin-4-yl and N-methylmorpholin-2-yl, or via the nitrogen atom, e.g., piperidin-1-yl (commonly called piperidino), morpholin-4-yl (commonly called morpholino), N-methylpiperazin-4-yl (commonly called N-methylpiperazino), 1H-1-imidazol-1-yl or 4H-1,2,4-triazol-4-yl. Azolyls, especially 1 H-1-imidazolyl and 1 H-1,2,4-triazolyl, and pyridyls, especially 2-pyridyl, and 2- or 3-thienyls are the preferred heterocyclyls.
Substituted heterocyclyls include (lower)alkyl heterocyclyls especially N-(lower)alkylheterocyclyls such as N-methylmorpholin-4-yl, N-ethylpiperazino, but also 2-methylpyrrolidino, 4-methylpiperidino, 5-methyl-1H-1,2,4-triazol-3-yl, 3-methyl-1-phenyl-1H-1,2,4-triazol-5-yl, and 2-methylpyridyl; (lower)alkanoyl heterocyclyls such as 2-acetylthiophenyl, 2-acetylpyrrolidino; haloheterocyclys such as 2-halo-3-thienyl, 2,5-dihalo-3-thienyl, and 5-halo-2-thienyl; N-(lower)alkanoyl heterocyclyls such as N-acetylpiperazino and 4-acetylpiperidino; and aryl substituted heterocyclyls include heterocyclyls substituted by aryl as defined herein such as N-phenylpiperazino, N-(4-chlorophenyl)piperazino, 2-(4-trifluoromethylphenyl)piperazino, and the like. Substituted azolyls, thiadiazolyls, thienyls, and pyridyls are the preferred substituted heterocyclyls.
By the term "(lower)alkynyl" as used herein is meant straight and branched chain alkynyl radicals of 2 to 8 carbon atoms, such as 1-butynyl.
The term "phenylalkyl" refers to phenyl(lower)alkyl, especially benzyl, a- and β-phenylethyl and a-, (3-and y-phenylpropyl. The preferred phenylalkyl is benzyl. Typical suitable aryl groups include phenyl, halo substituted phenyl such as 4-chlorophenyl or 4-fluorophenyl, 2,4-dichloro- or 2,4-difluorophenyl, 2,5-dichloro- or 2,5-difluorophenyl, 2,6-dichloro- or 2,6-difluorophenyl, 2,4,6-trichloro- or 2,4,6-trifluorophenyl and 2,3,4,6-tetrachloro- and 2,3,4,6-tetrafluorophenyl; (lower)alkanoyl substituted phenyl such as 4- acetylphenyl; phenyl substituted by-NR₄R₅ such as 4-(N,N-dimethylamino)phenyl; phenyl substituted by two different groups such as 4-nitro-3-trifluoromethylphenyl or 3-nitro-4-trifluoromethylphenyl; (lower)alkyl substituted phenyl such as 4-methylphenyl, 2,4-dimethylphenyl, 2,4,6-trimethylphenyl or 2,3,4,6-tetramethylphenyl; halo(lower)alkyl substituted phenyl such as 4-trifluoromethylphenyl, 4-(1,1-difluoroethyl)phenyl and similarly substituted phenylalkyl groups, especially similarly substituted benzyl groups. Difluoro and trifluorophenyl are preferred aryl groups; 2,6-difluorophenyl is more preferred.
The term "arylcarbonyl" refers to a carbonyl group bonded to substituted or unsubstituted phenyl or substituted or unsubstituted phenyl(lower)alkyl wherein the substituents comprise one to four of one or more groups selected from halogen, nitro, -NR₄R_s where R₄ and R_s are as defined previously, (lower)alkanoyl, (lower)alkyl, and halo(lower)alkyl.
Preferred OR₄ groups include benzoyloxy, benzyloxy, substituted benzoyloxy and substituted benzyloxy, said benzoyloxy and benzyloxy substituents being one to four of one or more groups selected from halogen, (lower)alkyl, halo(lower)alkyl, nitro, -NR₅R₆ where R_s and R₆ are as defined previously or (lower)alkanoyl and 2- or 5-halo-3-thienyl, 3-halo-2-thienyl or 2,5-dihalo-3-thienyl.
Typical suitable substituted benzyloxy groups include 4-chlorobenzyloxy, 4-fluorobenzyloxy, 2,4-dichloro- or 2,4-difluorobenzyloxy, 2-chloro-4-fluorobenzyloxy, 2,3-dichloro- or 2,3-difluorobenzyloxy, 2-chloro-3-fluorobenzyloxy, 2,5-dichloro- or 2,5-difluorobenzyloxy, 2-chloro-5-fluorobenzyloxy, 2,6-dichloro-or 2,6-difluorobenzyloxy, 2-chloro-6-fluorobenzyloxy, 2-, 3- or 4-trifluoromethylbenzyloxy, 2-, 3- or 4-methylbenzyloxy, and 2-, 3- or 4-acetylbenzyloxy. Halobenzyloxy groups are preferred; 2,6-difluorobenzyloxy and 2,4-difluorobenzyloxy are particularly preferred.
Typical suitable R₃ groups include 2-propynyl, 2-propenyl, propyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl, 1-methylpropyl, 2-butynyl, 2-butenyl, butyl, 1-methyl-2-butynyl, 1-methyl-2-butenyl, 2-methyl-2-butenyl, 2-ethyl-2-butenyl, 1-phenyl-2-propenyl, 2-phenyl-2-propenyl, 3-phenyl-2-propenyl, 3-phenyl-2-propynyl, 2-(4-fluorophenyl)-2-propenyl, 2-(4-chlorophenyl)-2-propenyl, 2-(2,4-difluorophenyl)-2-butenyl, 2-(2,4-dichlorophenyl)-butyl, 2-(4-nitro-3-trifluoromethyl)-2-propenyl, 2-piperazino-2-propenyl, 2-(N-acetylpiperazino)-2-butyl, 2-(N-propyl piperazino)-2-pentenyl, 2-(4-acetylpiperidino)-2-butenyl, 2-[N-(4-trifluoromethylphenyl)]piperazino-2-propenyl and 2-benzyl-2-propenyl, 2-(2,4-difluorobenzyl)-2-butenyl and the like. The cis- and trans- isomers, e.g. cis- and trans-2-butenyl, are also contemplated. Preferred R₃ groups include propyl, 2-propenyl, 2-propynyl, 2-aryl-2-propenyl such as 2-(2,4-difluorophenyl)-2-propenyl and 2-heterocyclyl-2-propenyl such as 2-(N-acetylpiperazino)-2-propenyl.
Compounds of the present invention can exist in two isomeric forms, i.e., cis-2,3 and trans-2,3. For example (±)-2-allyl-6-chloro-2,3-dihydro-3-hydroxyl-2-(1H-1-imidazolylmethyl)benzo[b]thiophene exists in the cis- and trans-forms as indicated by the following formulas
In the formula labelled cis-2,3, the hydroxy and 1 H-imidazolylmethyl groups are both positioned on the same side of the ring. In the trans-2,3 formula, the groups are positioned on opposite sides of the ring. Both forms are within the scope of the present invention, as are the individual optical isomers, e.g., (±)-cis-2,3 and (-)-cis-2,3 which can be obtained by resolution of a racemic mixture [(±)-cis-2,3] by conventional means well known to those skilled in the art, such as fractional crystallization or chromatography.
Preferred groups of compounds of this invention include those wherein:

(1) one of R' and R² is hydrogen and the other is hydroxyl, and/or
(2) n is 1; and/or
(3) Y is imidazol-1-yl, and/or
(4) R₃ is -CHR₇-CR₉=CHR₈.

Preferred compounds include:

2-allyl-6-chloro-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)benzo[b]thiophene,
2-allyl-6-chloro-2,3-dihydro-3-fluoro-2-(1H-1-imidazolylmethyl)benzo[b]thiophene,
2-allyl-3-(2-chloro-6-fluorobenzyloxy)-2,3-dihydro-6-fluoro-2-(1H-1-imidazolylmethyl)benzo[b]thiophene,
2-allyl-3-(2,6-difluorobenzyloxy)-2,3-dihydro-6-fluoro-2-(1H-1-imidazolylmethyl)benzo[b]thiophene,
2-allyl-2,3-dihydro-6-chloro-2-(1H-1-imidazolylmethyl)benzo[b]thiophene,
2-allyl-2,3-dihydro-5-fluoro-3-hydroxy-2-(1,2,4-triazol-1-ylmethyl)benzo[b]thiophene,
6-chloro-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)-2-[2-(4-chlorophenyl)-2-propenyl]benzo[b]-thiophene, and
6-chloro-2,3-dihydro-3-(1H-1-imidazolyl)-2-(1H-imidazol-1-ylmethyl)-2-allyl-benzo[b]thiophene.

The compounds of the present invention are made by the following process:
To produce a compound of formula I wherein R₁ and R₂, together with the carbon atom to which they are attached, form a carbonyl group and R₃ is -CHR₇-CR₉=CHR₈, heating a compound of formula V in solvent
to form a compound of formula la
wherein R,, R₈, Rg, X, Y, m and n are as previously defined.
Compounds of formula V may be formed by the following process.
Substituted hydroxy compounds of the formula II wherein X, Y, m and n have the meanings given above are reacted with an allyl compound of the formula III, i.e., e.g., allyl-LG wherein LG is a leaving group such as halide, e.g., bromide, tosylate, mesylate and wherein R₇, R_a and R₉ are as defined above, in the presence of an alkali metal base (MOH), a solvent or mixture of solvents for a time and temperature sufficient to give the substituted allyl ether of general formula IV to the compound of formula V as depicted in the following reaction scheme,
The reaction of the compounds of formula II with an alkali metal base, for example as alkali metal hydroxide especially NaOH or KOH or aqueous solutions thereof, alkali metal hydride, alkali metal amide or alkali metal alcoholate and an allyl compound of formula III, e.g., allyl bromide, is carried out in an aprotic organic solvent such as dimethylformamide, (DMF), dimethyl sulfoxide (DMSO), hexamethylphosphoric acid triamide (HMPTA), an ether such as tetrahydrofuran (THF), dioxane or dimethoxyethane, a lower alcohol, or a ketone, e.g. acetone, and in the presence of a phase transfer catalyst (PTC) such as tricaprylylmethylammonium chloride at 0-60°C, especially 20°-40°C for 1-6 hours.
Compounds of formula II are prepared in accordance with known methods, such as the procedures disclosed in U.S. Patent 4,352,808 at Col. 5, lines 13-43 and at Col. 11 line 1 to Col. 12 line 9 (Preparation No. 1). The preparation of many compounds of formula II is illustrated in the examples which follow.
Compounds of formula IV are oxidized to give the substituted sulfoxide of formula V.
The oxidation of IV is typically carried out by contacting compounds of formula IV with an oxidizing agent such as a peracid e.g., meta-chloroperbenzoic acid or peracetic acid, or hydrogen peroxide in an organic solvent such as halogenated alkanes, e.g., methylene chloride or chloroform, at about 0°-20°C, preferably 0°-5°C for about 1-4 hours.
The substituted compounds of formula V are heated in a suitable solvent and normally in the presence of an alkanoic acid anhydride for a time sufficient to give the substituted ketone compounds of formula la.
Typical suitable solvents include aromatic hydrocarbons such as benzene, xylenes, toluene, and halogenated alkanes such as chloroform.
Typical suitable alkanoic acid anhydrides include acetic anhydride, perchloroacetic anhydride and perfluoroacetic acid anhydride. Temperatures of about 50° to about 100°C for about 1 to 2 hours are normally sufficient.
The reaction of the compound of formula V to form a compound of formula la, which is in accordance with the invention, is followed if desired by one or more of sub-processes (i) to (xiii) listed below:

(i) to produce a compound of formula I wherein R, and R_2' together with the carbon atom to which they are attached, form the group
reacting a compound having the formula
with a compound having the formula
to form a compound having the formula
wherein L, and L₂ are lower alkyl groups, preferably methyl, and R₃, R₆, X, Y, Z, m, and n are as previously defined.
Compounds of the formulas Via and Vlb are standard chemical reagents such as disclosed in "Compendium of Organic Synthetic Methods" by I. T. Harrison and S. Harrison, Wiley-Interscience, pages 449-456, NY 1971 and "Steroid Reactions", C. Djerassi, Ed. Holden-Day Inc., pages 1-66 1963. For example, the ketals and thioketals of formula Ic and Ic' may be prepared by an exchange reaction of Ib with dioxolans and dithioxolans of formulas Via and Vlb, respectively,
in the presence of acids such as toluenesulfonic acid (TsOH) in a solvent such as methylene chloride.
Typical dioxolans of formula Via wherein Z is NH may be prepared by reductive amination of 2,2-dimethyl-4-formyl-1,3-dioxolans of the formula VII which are disclosed in Swiss Patent Appin. CH644,855A (8/31/84).
(ii) to produce a compound of formula I wherein R₁and R₂, together with the carbon atom to which they are attached form the group
reacting a compound having the formula
with a compound of the formula
to form a compound of the formula
wherein R₃, R₄, X, X, m, and n are as previously defined. The reaction takes place upon heating in the presence of a base such as sodium carbonate. A solvent such as methanol may be used. Preferably an acid addition salt of the compound R₄NH₂ is used, such as R₄NH₂ HCI.
(iii) to produce a compound of formula I wherein R, and R₂, together with the carbon atom to which they are attached, form a thiocarbonyl group, reacting a compound of the formula
with a sulfur-introducing reagent to form a compound having the formula
wherein R₃, X, Y, m, and n are as previously defined. Preferred sulfur-introducing groups are P₂S₅ and Lawesson's reagent.
(iv) to form a compound of formula I wherein one of R₁ is hydrogen and the other is hydroxyl, reducing a compound of the following formula with a metal boro hydride or aluminum hydride
to form a compound having the formula
wherein R₃, X, Y, m and n are as previously defined. Preferred metal borohydrides are alkali metal borohydrides, especially NaBH₄ and KBH₄ and preferred aluminum hydrides include LiAIH₄. The reaction takes place in a solvent such as a lower alkanol, e.g. methanol.
(v) To form a compound of formula I wherein one of R₁ and R₂ is hydrogen, and the other is -NR₄R₅, -OR₄, or-SR₅, reacting a compound of the formula
wherein R₂' is -OH, -SH, or -NH₂ with a compound of the formula
to form a compound of the formula
wherein R₂" is ―NR₄R₅, -OR₄, or ―SR₅, L₃ is a leaving group, and R₃, X, Y, m, and n are as previously defined. Typical leaving groups are halogen. The reaction takes place in presence of a base and in an organic solvent, e.g., DMF, HMPTA, an aromatic hydrocarbon, e.g., benzene ortoluene, orTHF or a dioxane or a lower alkanol or ketone, e.g., acetone conveniently at a temperature of about 20°-30°C.
Especially suitable compounds of the formula L₃-R₄ and L₅R₅ are substituted benzyl or benzoyl halides which are commercially available or are made by synthetic procedures well known in the art. Typical suitable substituted benzyl halides are the benzyl chlorides or bromides substituted by groups described in reference to the substituted benzyloxy groups above. Typical suitable benzoyl halides include 2-, 3-, or 4- monohalo (e.g., chloro or fluoro) benzoyl chloride and 2,4-dihalo, 2,5-dihalo or 2,6-dihalo (e.g., 2,6-difluorobenzoyl chloride). Suitable bases include sodium and potassium hydroxide, etc.
(vi) To make a compound of formula I wherein R₃ is-CHR₇-CHR₉-CH₂R₈, catalytically hydrogenating a compound of formula Ij
to form a compound having the formula Ik
wherein R₁, R₂, R₇, R_a, Rg, X, Y, m and n are as previously defined. Suitable catalysts include Pd/C, Rh/C, and Pt/C.
(vii) To produce a compound of formula I wherein R₃ is-CHR₇-C=CR₈, halogenating a compound of the formula
wherein R₁, R₂, R₇₁ R₈, X, Y, m and n are as previously defined, and reacting the so-obtained compound with strong base, preferably potassium or sodium hydroxide followed by reaction with potassium or sodium amide. The preferred halogen is bromine. The reaction sequence is presumed to be as follows (only R₃ is shown):
(viii) To product a compound of formula I wherein one of R₁ or R₂ is halogen, reacting a compound of the following formula lm
with a compound that replace hydroxy by halogen to form a compound of the formula In
wherein Hal represents halogen and R_i, R₃ X, Y, m and n are as previously defined. Typical compounds that replace hydroxy by halogen include SOCI₂, SOBr₂, PCl₅, PBr₃, and PCI₃.
(ix) To produce a compound offormula I wherein both R₁ and R₂ are hydrogen, reacting a compound of the following formula
with a halogen displacement agent to form a compound of the formula
wherein Hal is halogen and R₂, X, Y, m and n are as previously defined. The preferred halogen displacement agent is tri(n-butyl)tin hydride. The displacement takes place upon heating in solvent, such as toluene.
(x) To produce a compound wherein R₂ is substituted or unsubstituted heterocyclyl, said substituents being as previously defined, reacting a compound of the formula
with a compound of the formula
- H-Het
to form a compound of the formula
wherein Het is substituted or unsubstituted heterocyclyl, Hal is halogen, and R_i, R₃, X, Y, m, and are as previously defined. The reaction takes place upon heating in a solvent, such as DMF.
(xi) To produce a compound of formula I wherein one of R, and R₂ is (lower)alkyl or (lower)alkynyl and the other is hydroxyl, reacting a compound of the formula
with a compound that introduces hydrogen and a (lower)alkyl or (lower)alkynyl to form a compound of the formula
wherein Alk is (lower)alkyl or (lower)alkynyl and R₃, X, Y, m, and n are as defined previously.
Typical compounds that introduce hydrogen and a (lower)alkynyl group are (lower)alkynes such as 3,3-dimethyl-1-butyne. The reaction takes place at room temperature or below in solvent, such as THF.
Typical compounds that introduce hydrogen and a (lower)alkyl group are Grignard reagents such as CH₃MgBr, which are well known in the art. The reaction with the Grignard reagent takes place in solvent, such as THF, at room temperature or higher.
(xii) After the desired compound has been produced, it may be isolated from its optical isomers by chromatography or fractional crystallation.
(xiii) The compounds may be converted to pharmaceutically acceptable salts by known methods.

The compounds of this invention exhibit broad spectrum antifungal activity, in conventional antifungal screening tests, against human and animal pathogens, such as the following: Aspergillus, Candida, Geotrichum, Microsporum, Monosporium, Rhodotorula, Saccharomyces, Torulopsis and Trichophyton.
The compounds of this invention exhibit topical fungal activity in in vivo tests in animals that is superior to that for miconazole, a commercial product. For example, (±)-cis-2-allyl-6-chloro-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)-benzo[b]thiophene in a hamster vaginal Candida topical infection model is more potent than miconazole.
The present invention also provides a pharmaceutical composition comprising an effective antifungal amount of a compound represented by formula I or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.
The preferred pharmaceutically acceptable salts are nontoxic acid addition salts formed by adding to the compounds of the present invention about a stoichiometric amount of a mineral acid, such as HCI, HBr, H₂S0₄ or H₃PO₄, or of an organic acid, such as acetic, propionic, valeric, oleic, palmitic, stearic, lauric, benzoic, lactic, para-toluene sulfonic, methane sulfonic, citric, maleic, fumaric, succinic and the like.
The pharmaceutical compositions of the present invention may be adapted for oral, parenteral or topical administration. They are formulated by combining the compound of this invention or an equivalent amount of a pharmaceutically acceptable salt thereof with any suitable, inert, pharmaceutically acceptable carrier or diluent. The preferred mode of administration is topical.
Examples of suitable compositions include solid or liquid compositions for oral administration such as tablets, capsules, pills, powders, granules, solutions, dragees, suspensions or emulsions. They may also be manufactured in the form of sterile solid compositions which can be dissolved in sterile water, physiological saline or some other sterile injectable medium immediately before use.
Topical dosage forms may be prepared according to procedures well known in the art, and may contain a variety of ingredients, excipients and additives. The formulations for topical use include ointments, creams, lotions, powders, aerosols, pessaries and sprays. Of these, ointments, lotions and creams may contain water, oils, fats, waxes, polyesters, alcohols, or polyols, plus such other ingredients as fragrances, emulsifiers and preservatives. Powders are made by mixing the active ingredient with a readily available, inert, pulverous distributing agent, such as talcum, calcium carbonate, tricalcium phosphate, or boric acid. Aqueous suspensions of the above powders may also be made. Solutions or emulsions may also be prepared using inert solvents which are preferably nonflammable, odorless, colorless and nontoxic, for example, vegetable oils and isopropanol. Similarly, aerosol or non-aerosol sprays may be prepared using solutions or suspensions in appropriate solvents, e.g., difluorodichloromethane for aerosols.
Parenteral forms to be injected intravenously, intramuscularly, or subcutanteously are usually in the form of a sterile solution, and may contain salts or glucose to make the solution isotonic.
Based on the greater in vivo topical potency for the compounds of this invention compared to miconazole, the dosages of the compounds of the present invention employed to combat a given fungal infection in animals, e.g., mammals, including humans, is generally somewhat less than the dosage requirements of present commercial products such as micoazole.
It will be appreciated that the actual preferred dosages of the compounds of the present invention or pharmaceutically acceptable salts thereof will vary according to the particular composition formulated, the mode of application and the particular situs, host and disease being treated. Many factors that modify the action of the drug will be taken into account by the attending clinician, e.g., age, body weight, sex, diet, time of administration, rate of excretion, condition of the host, drug combinations, reaction sensitivities and severity of the disease. Administration can be carried out continuously or periodically within the maximum tolerated dose. Optimal application rates for a given set of conditions can be readily ascertained by the attending clinician using conventional dosage determination tests.
In general, the topical dosage for humans ranges from about 50 mg per day to about 800 mg per day, in single or divided doses, with about 100 mg to about 200 mg per day being preferred. Each dose should be mixed with about 10 g of carrier.
In general, the oral dosage for human ranges from about 50 mg to about 800 mg per day, in single or divided doses, with about 100 mg to about 400 mg per day being preferred.
In general, the parenteral dosage for humans ranges for about 5 mg per day to about 50 mg per day, in single or divided doses, with about 10 mg per day being preferred.
The following Examples illustrate the invention.

Preparation 1:

(±)-Cis-2,3-dihydro-3-hydroxy-2-(1H-1-imidzoiy!methy!)benzo[b]thiophenes

A) (±)-cis-6-Chloro-2,3-dihydro-3-hydroxy-2-(1H-1-imidzolylmethyl)benzo[b]thiophene

1) 3-Bromo-7-ch/orothiochroman-4-one

Dissolve 7-chlorothiochroman-4-one (10 g, 50.3 mmole) in chloroform (100 mL) and cool the solution to 0-5°C. Add bromine (2.60 mL, 50.3 mmole) dropwise over a 10-minute period. Stir the reaction mixture at room temperature for one hour, then add chloroform (100 mL) and extract with 10% aqueous sodium sulfite (100 mL) followed by water (200 mL). Dry the chloroform solution over anhydrous magnesium sulfate, filter and evaporate in vacuo to a residue. Recrystallize the residue from cyclohexane to give 3-bromo-7-chlorothiochroman-4-one, mp 109-110°C.

2) 3-Bromo-7-ch/orothiochroman-4-o/

Suspend 3-bromo-7-chlorothiochroman-4-one (59.6 g, 215 mmole) in methanol (500 mL), cool to 05°C, and with stirring add sodium borohydride (8.18 g, 215 mmole) in three portions. After stirring the reaction mixture at room temperature for three hours, pour it into ice water (4 liters) and extract with chloroform (2 liters). Dry the chloroform solution over anhydrous magnesium sulfate, filter and evaporate in vacuo to a residue. Triturate the residue with chloroform/hexane to give 3-bromo-7-chlorothiochroman-4-ol, mp 141-142°C.

3) (±)-cis-6-Chloro-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)benzo[b]thiophene

Add 3-bromo-7-chlorothiochroman-4-ol (5.27 g, 18.8 mmole) and imidzole (12.8 g, 188 mmole) to acetonitrile (100 mL), and reflux for 4 hours. Pour the reaction mixture into water (500 mL), and extract with chloroform (500 mL). Wash the organic layer with water (500 mL), dry it over anhydrous magnesium sulfate, filter and evaporated in vacuo. Triturate the residue with anhydrous ether, filter and recrystallize from acetonitrile to give (±)-cis-6-chloro-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)benzo-[b]thiophene, m.p. 164-165°C.

B) In the procedure of above Preparation 1A (1-3), substitute for the 7-chlorothiochroman-4-one an equivalent quantity of each of the following:

a) thiochroman-4-one,
b) 6-chlorothiochroman-4-one,
c) 8-chlorothiochroman-4-one,
d) 5,7-dichlorothiochroman-4-one,
e) 6,7-dichlorothiochroman-4-one,
f) 6,8-dichlorothiochroman-4-one,
g) 7-trifluoromethylthiochroman-4-one,
h) 6-trifluoromethylthiochroman-4-one,
i) 6-fluorothiochroman-4-one,
j) 7-fluorothiochroman-4-one,
k) 8-fluorothiochroman-4-one,
I) 6,7-difluorothiochroman-4-one,
m) 6-methylthiochroman-4-one,
n) 7-isopropylthiochroman-4-one,
o) 6-cyanothiochroman-4-one,
p) 7-cyanothiochroman-4-one,
q) 6-nitrothiochroman-4-one,
r) 7-nitrothiochroman-4-one,
s) 6-nitro-7-trifluoromethylthiochroman-4-one,
t) 6-(2,6-difluorophenyl)-thiochroman-4-one,
u) 7-(2,6-difluorophenyl)-thiochroman-4-one,
v) 6-(2-chloro,6-fluorophenyl)-thiochroman-4-one,
w) 7-(2,4,6-trifluorophenyl)-thiochroman-4-one,

a) (±)-cis-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)benzo[b]thiophene,
b) (±)-cis-5-chloro-2,3-dihydro-3-hydroxy-2-(1H-1-(1H-1-imidazolylmethyl)benzo[b]thiophene,
c) (±)-cis-7-chloro-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)benzo[b]thiophene,
d) (±)-cis-4,6-dichloro-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)benzo[b]thiophene,
e) (±)-cis-5,6-dichloro-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)benzo[b]thiophene,
f) (±)-cis-5,7-dichloro-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)benzo[b]thiophene,
g) (±)-cis-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)-6-trifluoromethylbenzo[b]thiophene,
h) (±)-cis-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)-5-trifluoromethylbenzo[b]thiophene,
i) (±)-cis-2,3-dihydro-5-fluoro-3-hydroxy-2-(1H-1-imidazolylmethyl)benzo[b]thiophene,
j) (±)-cis-2,3-dihydro-6-fluoro-3-hydroxy-2-(1H-1-imidazolylmethyl)benzo[b)thiophene,
k) (±)-cis-2,3-dihydro-7-fluoro-3-hydroxy-2-(1H-1-imidazolylmethyl)benzo[b]thiophene,
I) (±)-cis-5,6-difluoro-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)benzo[b]thiophene,
m) (±)-cis-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)-5-methylbenzo[b] thiophene,
n) (±)-cis-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)-6-isopropylbenzo[b]thiophene,
o) (±)-cis-5-cyano-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)benzo[b]thiophene,
p) (±)-cis-6-cyano-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)benzo[b]thiophene,
q) (±)-cis-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)-5-nitrobenzo[b]thiophene,
r) (±)-cis-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)-6-nitrobenzo[b]thiophene,
s) (±)-cis-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)-5-nitro-6-trifluoromethylbenzo[b]-thiophene,
t) (±)-cis-5-(2,6-difluorophenyl)-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)benzo[b]-thiophene,
u) (±)-cis-6-(2,6-difluorophenyl)-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)benzo[b] thiophene,
v) (±)-cis-5-(2-chloro-6-fluorophenyl)-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)benzo[b]-thiophene,
w) (±)-cis-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)-6-(2,4,6-trifluorophenyl)-benzo[b]-thiophene,

Example 1

(±)-2-Allyl-6-chloro-2,3-dihydro-2-(1H-1-imidzolylmethyl)benzo[b]thiophene-3-one

A. (±)-cis-3-Allyloxy-6-chloro-2,3-dihydro-2-(1H-1-imidazolylmethyl)benzo[b]thiophene

Stir a mixture of 3.0 g (0.01 moles) of (±)-cis-6-chloro-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)benzo[b]thiophene, 3.44 g (0.045 mole) of allyl chloride, 25 mL of 50 wt% sodium hydroxide and 3 drops of tricaprylylmethylammonium chloride in 50 mL of THF overnight. Dilute the reaction mixture with 300 mL of methylene chloride. Separate the organic layer and wash it with water, and dry over anhydrous magnesium sulfate. Evaporate the organic solvents to give 3.2 g of the title compound, m/e of the molecular ion (hereinafter "m/e") 306.

B. (±)-cis-3-Allyloxy-6-chloro-2,3-dihydro-2-(1H-1-imidazolylmethyl)benzo[b]thiophene-1-oxide

Dissolve 21.7 g (70.7 mmole) of (±)-cis-3-allyloxy-6-chloro-2,3-dihydro-2-(1H-1-imidazolylmethyl)benzo[b]thiophene in 500 mL of CH₂CI₂ and cool the solution to 0-5°. Added 14.6 g (70.7 mmole) of m-chloroperoxybenzoic acid (tech. 80-85%) and stir the reaction mixture at 0-5° for 1 hour. Extract the reaction mixture with 500 mL of 5% aqueous NaHCO₃ followed by 500 mL of H₂0. Dried the CH₂CI₂ layer over anhydrous MgSO₄ and concentrate it to give (±)-cis-3-allyloxy-6-chloro-2,3-dihydro-2-(1H-1-imidazolylmethyl)benzo[b]thiophene-1-oxide, a gum, m/e 322.
Fractionally crystallize the mixture of (±)-cis and (±)-trans isomers from acetonitrile to give the (±)-cis isomer of the title compound (mp 168°C; m/e 306) and a mother liquor which provides the (±)-trans isomer of the title compound (mp 13D-132°C, m/e 306).

Example 3

(±)-cis-and (±)-trans-6-Chloro-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)-2-[2-(4-chlorophenyl)-2-propenyl]benzo[b]thiophene

A. (±)-cis-6-Chloro-2,3-dihydro-2-(1H-1-imidazolylmethyl)-3-[2-(4-chlorophenyl)-2-propenyloxy]benzo-[b]thiophene

Dissolve 2.665 g (10 mmole) of the compound of Preparation 1 (A)(3) in 50 mL of THF and 25 mL of 50% aqueous NaOH. To the solution so formed, add, with stirring, 2.315 g (10 mmole) of a-bromomethyl-4-chlorostyrene and 3-5 drops of tricaprylylmethyl ammonium chloride. Continue to stir the reaction mixture overnight at room temperature and add 500 mL of CHCl₃. Wash the organic layer with water until the pH of the aqueous layer is about 7. Dry the organic layer over anhydrous magnesium sulfate, filter and evaporate in vacuo to a residue. Chromatograph the residue on a silica gel column, eluting with CHCl₃ to give the title compound, m/e 417.

B. (±)-cis-6-Chloro-2,3-dihydro-2-(1H-1-imidazolylmethyl)-3[2-(4-chlorophenyl)-2-propenyloxy]benzo[b]thiophene-1-oxide

Add 1.61 g (9.32 mmole) of m-chloroperbenzoic acid to a solution of 2.50 g (5.7 mmole) of the compound of Example 3A in 100 mL of CH_ZCl₂. Stir the reaction mixture at room temperature for 2 hours. Wash the reaction mixture with 5% aqueous sodium bicarbonate and water. Dry the organic layer over anhydrous magnesium sulfate, filter and evaporate in vacuo to give the title compound as a gum, m/e 433.

C. (±)-6-Chloro-2,3-dihydro-2-(1H-1-imidazolylmethyl)-2-[2-(4-chlorophenyl)-2-propenyl]benzo[b]-thiophene-3-one

Reflux a solution of 2.50 g (5.7 mmole) of the compound of Example 3B and 2.42 g (11.5 mmole) of trifluoroacetic anhydride in 100 mL of toluene for hour. Evaporate the solution to dryness and dissolve the residue with methylene chloride. Wash the solution so formed with water. Dry the solution over anhydrous magnesium sulfate, filter and evaporate to give a gum. Chromatograph the gum on a silica gel column, eluting with CHCl₃ to give the title compound as an oil, m/e 416.

D. (±)-cis- and (±)-trans-6-Chloro-2,3-dihydro-3-hydroxy-2-1lH-1-imidazolylmethyl)-2-[2-(4-chlorophenyl)-2-propenyl]benzo[b]thiophene

Dissolve 0.700 g (1.69 mmole) of the compound of Example 3C in 25 mL of methanol and cool the solution so formed to 0°C. Add, with stirring, 0.064 g (1.69 mmole) of NaBH₄. Continue stirring at 0°C for 2 hours. Evaporate the methanol and dissolve the residue in 500 mL of CHCl₃. Wash the CHCI₃ solution over anhydrous magnesium sulfate, filter and evaporate to give a residue. Purify the residue by flash chromatography on silica gel (TLC grade), eluting with ethyl acetate to give a solid. Crystallize the solid from ethyl acetate to give the title compound (a mixture of cis and trans isomers) as an off-white solid, mp 165--168°C, m/e 418.

Example 4

(±)-cis-2-Allyl-6-chloro-3-(2-chloro-6-fluorobenzyloxy)-2,3-dihydro-2-(1H-1-imidazolylmethyl)-benzo[b]thiophene

Dissolve 1.0 g (3.20 mmole) of the (±)-cis-isomer of Example 2 in 10 mL of dimethylformamide (DMF). Add 0.313 g (6.52 mmole) of 50% dispersion of sodium hydride in mineral oil and stir the reaction mixture for 30 minutes at room temperature. Add 0.83 mL (6.52 mmole) of 2-chloro-6-fluorobenzyl chloride (Aldrich Chemical Co.) and stir the reaction mixture for 1 hour at room temperature. Pour the mixture into 500 mL of diethyl ether and 500 mL of water. Stir for 5 minutes. Separate the layers and wash the organic layer with water. Dry the organic layer over anhydrous magnesium sulfate and evaporate in vacuo to give a gum. Chromatograph the gum on silica gel, eluting with CHCl₃ to give the title compound as a gum, m/e 448.

Example 5

(±)-cis-2-Allyl-3-(2-chloro-6-fluorobenzyloxy)-2,3-dihydro-5-fluoro-2-(1H-1-imidazolylmethyl)benzo-[b]thiophene

A. (±)-3-Allyloxy-2,3-dihydro-5-fluoro-2-(1H-1-imidazolylmethyl)benzo[b]thiophene

Follow the procedure of Example 3A but substitute equivalent quantities of (±)-cis-2,3-dihydro-6-fluoro-3-hydroxy-2-(1H-1-imidazolylmethyl)benzo[b]thiophene (Preparation 1(B)(j) and allyl bromide for the compound of Preparation 1(A)(3) and a-bromomethyl-4-chlorostyrene, respectively, to give the title compound of this Example, Part A.

B. (±)-cis-3-Allyloxy-2,3-dihydro-5-fluoro-2,3-dihydro-2-(1H-1-imidazolylmethyl)benzo[blthiophene- 1- oxide

Follow the procedure of Example 3B but substitute an equivalent quantity of the title compound of Example 5A for (±)-cis-6-chloro-2,3-dihydro-2-(1H-1-imidazolylmethyl)-3-[2-(4-chlorophenyl)-2-propenyloxy]-benzo[b]thiophene to give the title compound of this Example, Part B.

C. (±)-cis- and (±)-trans-2-Allyl-2,3-dihydro-5-fluoro-3-hydroxy-2-(1H-1-imidazolylmethyl)-benzo[b]thiophene

Follow the procedure of Example 3C but substitute an equivalent quantity of the compound of Example 5B for the title compound of Examle 3C to give the corresponding benzo[b]thiophene-3-one which is thereafter treated in accordance with the procedure of Example 3D to provide the mixture of (±)-cis and (±)-trans-isomers of the title compound of this Example. Fractionally crystallize the mixture to obtain the title compounds of this Example, Part C.

D. (±)-cis-2-Allyl-3-(2-chloro-6-fluorobenzyloxy)-2,3-dihydro-5-fluoro-2-(1H-1-imidazolylmethyl)-benzo[b]thiophene

Dissolve 2.0 g (6.89 mmoles) of the (±)-cis isomer of the title compound of Example 5C in 50 mL of DMF. Add, with stirring, 0.662 g (13.8 mmoles) of sodium hydride (a 50% dispersion in mineral oil) and continue stirring the slurry so formed at room temperature for 30 minutes. Add 1.31 mL (10.3 mmoles) of 2-chloro-6-fluorobenzyl chloride and continue stirring at room temperature for 1 hour. Pour the reaction mixture into a mixture of 1 liter of ethyl ether and 1 liter of water. Stir the mixture so formed for 10 minutes. Separate the layers and wash the organic layer with 1 liter of water. Dry the organic layer over anhydrous magnesium sulfate, filter and evaporate in vacuo to give a residue. Chromatograph the residue on silica gel, eluting with CHCI₃ to give the title compound as a gum, m/e 432.

Example 6

(±)-2-Allyl-3,6-dichloro-2,3-dihydro-2-(1H-1-imidazolylmethyl]benzo[b]thiophene

Heat a solution of 2 g (6.5 mmoles) of the (±)-cis isomer of Example 2 and 3.8 g (32.6 mmoles) of thionylchloride in 50 mL of benzene at reflux for 2 hours. Evaporate the reaction mixture to dryness to give the title compound as a gum, m/e 324.

Example 7

(±)-2-Allyl-6-chloro-2,3-dihydro-3-fluoro-2-(1H-1-imidazolylmethyl)benzo[b]thiophene

Dissolve 1.0 g (3.25 mmoles) of the (±)-cis isomer of Example 2 in 50 mL of tetrahydrofuran and cool the solution to 0°-5°C. Add, with stirring, 1.06 g (6.50 mmoles) of diethylaminosulfur trifluoride ("DAST", obtained from Aldrich Chemical Co.) and continue to stir the reaction mixture for 1 hour. Evaporate the reaction mixture to give a residue. Triturate the residue with methylene chloride and wash the organic solution so formed with water. Dry the organic layer over anhydrous magnesium sulfate, filter and evaporate to give the title compound, m/e 308.

Example 8

(±)-cis and (±)-trans-2-Allyl-6-chloro-2,3-dihydro-3-(1H-1-imidazolyl)-2-(1H-1-imidazolylmethyl)-benzo[b]thiophene

Heat a solution of 2.0 g (6.1 mmoles) of the title compound of Example 6 and 0.9 g (13.2 mmoles) of imidazole in 50 mL of DMF at 100°C overnight. Evaporate the solution to a residue. Triturate the residue with CHCI₃ and wash the CHCI₃ solution with water. Dry the organic layer over anhydrous magnesium sulfate, filter and evaporate to give a residue. Chromatograph the residue on silica gel, eluting with 1:99 (v/ v) CH₃OH:CHCl₃ to give the cis and trans title compounds as gums, m/e 357 for each isomer.

Example 9

(±)-2-Allyl-6-chloro-2,3-dihydro-2-(1H-1-imidzolylmethyl)benzo[b]thiophene

Heat a reaction mixture of 1.4 g (4.3 mmoles) of the title compound of Example 6 and 2.5 g (8.5 mmoles) of tri(n-butyl)tin hydride in 20 mL of toluene at reflux overnight. Evaporate to give a residue. Chromatograph the residue on silica gel, eluting with 1:1 (v/v) ethyl acetate:hexane to give the title compound as an oil, m/e 290.

Example 10

(±)-cis-N,N-Dimethyl-O-[2-allyl-6-chloro-2-(1H-1-imidazolylmethyl)benzo[b]thiophene-3-yl]thiocarbamate

Dissolve 1.0 g (3.2 mmoles) of the (±)-cis isomer of the title compound of Example 2 in 25 mL of DMF. Add, with stirring, 0.086 g (3.58 mmoles) of sodium hydride, (as a 50% dispersion in mineral oil) and continue stirring at room temperature for 1 hour. Add to the stirred solution 0.6 g (4.85 mmoles) of dimethylthiocarbamoyl chloride (Aldrich Chemical Co.) and continue to stir the reaction mixture overnight. Evaporate the reaction mixture to a residue. Triturate the residue with methylene chloride. Wash the organic layer with water. Dry the organic layer over anhydrous magnesium sulfate, filter and evaporate to give an oil. Chromatograph the oil on silica gel, eluting with 1:99 (v/v) CH₃OH:CHCl₃ to give the title compound as a gum, m/e 394.

Example 11

(±)-cis and (±)-trans-2-Allyl-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)benzo[b]thiophenes

Follow the procedure of Example 3A but substitute quantities of each of the (±)-cis-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)benzo[b]thiophene compounds a)-v) obtained in Preparation 1B for the compound of Preparation 1(A)(3) and allyl chloride for a-bromomethyl-4-chlorostyrene. There are obtained the corresponding 3-allyloxy derivatives of each of the foregoing, which upon reaction with m-chloroperbenzoic acid according to the procedure of Example 3B provide the corresponding benzo[b]thiophene-1-oxide derivatives which are treated with trifluoroacetic anhydride and thereafter with NaBH₄ in accordance with the procedures of Examples 3C and 3D to provide mixtures of (±)-cis and (±)-trans isomers which are separated into the (±)-cis isomers,

a) (±)-cis-2-Allyl-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)benzo[b]thiophene,
b) (±)-cis-2-Allyl-5-chloro-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)benzo[b]thiophene,
c) (±)-cis-2-Allyl-7-chloro-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)benzo[b]thiophene,
d) (±)-cis-2-Allyl-4,6-dichloro-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)benzo[b]thiophene,
e) (±)-cis-2-Allyl-5,6-dichloro-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)benzo[b]thiophene,
f) (±)-cis-2-Allyl-5,7-dichloro-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)benzo[b]thiophene,
g) (±)-cis-2-Allyl-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)-6-trifluoromethylbenzo[b]-thiophene,
h) (±)-cis-2-Allyl-2,3-dihydro-3-hydroxy-2-(1H-1-imidzolylmethyl)-5-trifluoromethylbenzo[b]thiophene,
i) (±)-cis-2-Allyl-2,3-dihdyro-5-fluoro-3-hydroxy-2-(1H-1-imidazolylmethyl)benzo[b]thiophene,
j) (±)-cis-2-Allyl-2,3-dihydro-6-fluoro-3-hydroxy-2-(1H-1-imidazolylmethyl)benzo[b]thiophene,
k) (±)-cis-2-Allyl-2,3-dihydro-7-fluoro-3-hydroxy-2-(1H-1-imidazolylmethyl)benzo[b]thiophene,
I) (±)-cis-2-Allyl-5,6-difluoro-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)benzo[b]thiophene,
m) (±)-cis-2-Allyl-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)-5-methylbenzo[b]thiophene,
n) (±)-cis-2-Allyl-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)-6-isopropylbenzo[b]thiophene,
o) (±)-cis-2-Allyl-5-cyano-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)benzo[b]thiophene,
p) (±)-cis-2-Allyl-6-cyano-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)benzo[b]thiophene,
q) (±)-cis-2-Allyl-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)-5-nitrobenzo[b]thiophene,
r) (±)-cis-2-Allyl-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)-6-nitrobenzo[b]thiophene,
s) (±)-cis-2-Allyl-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)-5-nitro-6-trifluoromethyl- benzo[b]thiophene,
t) (±)-cis-2-Allyl-5-(2,6-difluorophenyl)-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)-benzo[b]thiophene,
u) (±)-cis-2-Allyl-6-(2,6-difluorophenyl)-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)-benzo[b]thiophene,
v) (±)-cis-2-Allyl-5-(2-chloro-6-fluorophenyl)-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)-benzo[b]thiophene,
w) (±)-cis-2-Allyl-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)-6-(2,4,6-trifluorophenyl)-benzo[b]thiophene,

Example 12

(±)-cis- and (±)-trans-2-Allyl-2,3-dihydro-5-fluoro-3-hydroxy-2-(1H-1,2,4-triazol-1-ylmethyl)benzo[b]-thiophene

Follow the procedure of Example 3A but substitute equivalent quantities of (±)-cis-2,3-dihydro-5-fluoro-3-hydroxy-2-(1H-1,2,4-triazol-1-ylmethyl)benzo[b]thiophene for the compound of Preparation 1 (A)(3) and of allyl chloride for a-bromoethyl-4-chlorostyrene. There is obtained the corresponding 3-allyloxy derivative which upon reaction with m-chloroperbenzoic acid according to the procedure of Example 3B provides the corresponding benzo[b]thiophene-1-oxide derivate which is treated with trifluoroacetic anhydride and thereafter with NaBH₄ in accordance with the procedures of Example 3C and 3D to provide a mixture of the (±)-cis and (±)-trans-isomers which is separated by fractional crystallization into the title compounds, mp 149-150°C and 157-159°C, respectively, both white solids.

Example 13

(±)-cis- and (±)-trans-2-Allyl-6-chloro-2,3-dihydro-2-(1H-1-imidazolylmethyl)-3-(2,4-dichlorobenzoyloxy)-benzo[b]thiophene

Stir a mixture of 1 g (3.2 mmoles) of the title compounds of Example 2, 1.36 g (6.49 mmoles) of 2,4-dichlorobenzoyl chloride and 0.66 g (6.52 mmoles) of trimethylamine in 50 mL of methylene chloride at room temperature for 4 hours. Dilute the reaction mixture with water. Separate the organic phase and wash the organic phase with 5 wt% sodium bicarbonate and then with water. Dry over anhydrous magnesium sulfate and evaporate the organic solvent to give an oil. Chromatograph the oil on a silica gel column, eluting with chloroform to give the (±)-cis and (±)-trans title compound, each having m/e 479.

Example 14

(±)-cis-and (±)-trans-2-allyl-6-chloro-3-[(4-chlorophenoxy)ethoxy]-2,3-dihydro-2-(1H-1-imidazolylmethyl)benzo[b]thiophene

Add 0.086 g (3.43 mmoles) of sodium hydride 50% oil dispersion to a solution of 1 g (3.2 mmoles) of the title compounds of Example 2 in 20 mL of DMSO. Stir the resulting slurry for 1 hour and add thereto 1.63 g (6.5 mmoles) of 1-(4-chlorophenoxy)-2-mesylethane. Heat the reaction mixture overnight. Extract the reaction mixture with methylene chloride. Wash the organic layer with water and dry it over anhydrous MgS0₄. Evaporate the solvent to give a gum. Chromatograph the gum on a silica gel column, eluting the chloroform to give 278 mg of the title compounds as an oil, m/e 461.

Example 15

(±)-cis- and (±)-trans-2-Allyl-6-chloro-2,3-dihydro-2-(1H-1-imidazolylmethyl)-3-(1H-1,2,4-triazolylmethoxy)-benzo[b]thiophene

Add 0.96 g (20 mmoles) of sodium hydride (50% oil dispersion) to a solution of 1.0 g (3.26 mmoles) of the title compounds of Example 2 in 10 ml of DMF. Stir for 30 minutes at RT. Add dropwise a solution of 2.43 g (10 mmoles) of 1-bromomethyl-1,2,4-triazole hydrogen bromide in 10 mL of DMF. Stir the reaction mixture overnight at RT. Pour the reaction mixture into 500 mL of CHCI₃and 500 mL of brine and stir for 10 minutes. Separate and dry the organic layer over anhydrous MgSO₄. Remove the organic solvent in vacuo to give an oily residue. Chromatograph the oily residue on silica gel, eluting with 1:99 (v/v) MeOH:CHCl₃ containing 1% (v/v) of conc. NH₄OH to give 0.75 g of the title compounds, m/e 387.

Example 16

(±)-cis- and (±)-trans-2-Allyl-3-allyloxy-6-chloro-2,3-dihydro-2-(1H-1-imidazolylmethyl)benzo[b]thiophene

Add 0.32 mL (3.66 mmoles) of allyl bromide and two drops of tricaprylylmethylammonium chloride to a solution of 0.75 g (2.44 mmoles) of the title compounds of Example 2 and 10 mL of 50% of NaOH in 30 mL of THF. Stir the reaction mixture at RT for 3 hours. Pour the reaction mixture into 250 mL of CHCI₃ and 250 mL of brine and stir for 5 minutes. Separate and dry the organic layer over anhydrous MgS0₄. Remove the organic solvent in vacuo to give an oily residue. Chromatograph the oily residue on a silica gel column, eluting with CHCI₃ to give 0.83 g of the title compounds, m/e 346.

Example 17

(±)-cis- and (±)-trans-2-Allyl-5-fluoro-3-(1H-1,2,4-triazoylmethoxy)-2-(1H-1,2,4-triazolylmethyl)-benzo[b]thiophene

Add 0.96 g 20 mmoles) of sodium hydride (50% oil dispersion) to a solution of 0.895 g (3.07 mmoles) of the title compounds of Example 12 in 10 mL of DMF and stir for 30 minutes at RT. Add dropwise thereto a solution of 2.43 g (1.0 mmoles) of 1-bromomethyl-1 H-1,2,4-triazole hydrogen bromide in 10 mL of DMF. Stir the reaction mixture for 1 hour at RT. Pour the reaction mixture into 500 mL of CHCI₃ and 500 mL of brine. Separate and dry the organic layer over anhydrous MgSO₄. Remove the organic solvents in vacuo to give an oily residue. Chromatograph the oily residue on a silica gel column, eluting with 1:99 (v/v) MeOH:CHCl₃ containing 1 volume % of concentrated NH₄OH to give 1.04 g of the title compounds, m/e 372.

Example 18

A. 2-Allyl-2,3-dihydro-2-(1H-1,2,4-triazolylmeihyl)-6-fluoro benzo[b]thiophene-3-one

Follow the procedure of Example 12, which is similar to that of Example 3, but omit the step that is similar to Step D, Example 3 to yield the title compound of the Example, Part A.

B. (±)-cis- and (±)-trans-2-Allyl-2,3-dihydro-3-[1-(3,3-dimethyl-1-butynyl)1-5-fluoro-3-hydroxy-2-(1H-1,2,4-triazolylmethyl)benzo[b]thiophene

Add 12.0 mL (18.6 mmoles) of n-butyl lithium (1.55 M in hexane) to a solution of 2.0 mL (16.2 mmoles) of 3,3-dimehtyl-1-butyne in 50 mL of dry THF at a temperatrure of 0°-5°C. Stir for 30 minutes at 0°-5°C. Add thereto 2.0 g (6.92 mmoles) of the title compound of Part A. Stir the reaction mixture so formed overnight at RT. Pour the reaction mixture into one liter of CHCI₃. Wash the organic layer with one liter of brine. Separate and dry the organic layer over anhydrous MgS0₄. Remove the organic solvents in vacuo to give a gum. Chromatograph the gum on a silica gel column, eluting with CHCI₃ to give 0.429 g of the less polar title compounds, as a solid, mp 166°-167°C, m/e 369, and 0.541 g of the more polar title compound as a gum, m/e 369.

Example 19

A. 6-Fluoro-2-Allyl-2,3-dihydro-2-(1H-1-imidazolylmethyl)benzo[b]thiophene-3-one

Follow the procedure of Exmaple 11j, which is similar to that of Example 3, but omit the step that is similar to step D of Example 3 to yield the title compound of this Example, part A.

B. (±)-cis- and (±)-trans-2-Allyl-2,3-dihydro-6-fluoro-3-hydroxy-2-(1H-1-imidazolylmethyl)-benzo[b]thiophene

Add 4.1 mL (11.6 mmoles) of 2.8M CH₃MgBr to a suspension of 1.67 g (5.79 mmoles) of the compound of Part A in 25 mL of THF. Stir the reaction mixture for 1 hour at RT and then heat at reflux for 2 hours. Add 25 mL of 10% NH_QCl and stir for 10 minutes. Pour into 500 mL of CHCI₃ and 500 mL of brine. Remove the solvent in vacuo to give an oily residue. Chromatograph the oily residue on a silica gel column, eluting with 1:99 (v/v) MeOH:CHCl₃ containing 1 vol% of conc. NH₄0H to give 0.281 g of the less polar title compound, m/e 304 and 0.303 g of the more polar isomer, m/e 304.

Formulations

The following are typical pharmaceutical formulations containing as the active ingredient (designated "Drug") the compound of this invention such as (±)-cis-2-allyl-6-chloro-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)benzo[b]thiophene or (±)-cis-2-allyl-6-chloro-3-(2-chloro-6-fluorobenzyloxy)-2,3-dihydro-2-(1H-1-imidzolylmethyl)benzo[b]thiophene. It will be appreciated, however, that either of these compounds may be replaced by equally effective quantities of other compounds of this invention.

Formulation 1

Procedure:

Heat the polyethylene glycol 6000 to 70-80°C. Mix the drug, sodium lauryl sulfate, corn starch, and lactose into the liquid and allow the mixture to cool. Pass the solidified mixture through a mill. Blend granules with magnesium stearate and compress into tablets.

Formulation 2

Procedure:

Mix the first four ingredients in a suitable mixer for 10-15 minutes. Add the magnesium stearate and mix for 1-3 minutes. Fill the mixture into suitable two-piece hard gelatin capsules using an encapsulating machine.

Claims

1. A compound represented by the formula I

in racemic or optically active form, or a pharmaceutically acceptable salt thereof wherein

X is one or more groups selected independently from halogen, C_1-6 alkyl, halo C_1-6 alkyl, cyano, nitro or substituted and unsubstituted phenyl, or substituted or unsubstituted phenyl C_1-6 alkyl wherein the substituents comprise one to four of one or more groups selected from halogen, nitro, -NR₄R₅, C₂-₁ alkanoyl, C_1-6 alkyl, and halo C_1-6 alkyl;

Y is substituted or unsubstituted imidazolyl or substituted or unsubstituted 1,2,4-triazolyl, said substituents being one or more groups selected independently from C_1-6 alkyl substituted or unsubstituted or substituted and unsubstituted phenyl, or substituted or unsubstituted phenyl C_1-6 alkyl wherein the substituents comprise one to four of one or more groups selected from halogen, nitro, -NR₄R₅, C₂-₁ alkanoyl, C_1-6 alkyl, and halo C_1-6 alkyl;

R₁ and R₂ are independently hydrogen, -CH₂NR₄R₅, -NR₄R₅, -OR₄, -SR_S, C_1-6 alkyl, C_2-8 alkynyl, halogen, or substituted and unsubstituted phenyl, or substituted or unsubstituted phenyl C_1-6 alkyl wherein the substituents comprise one to four of one or more groups selected from halogen, nitro, ―NR₄R_5,; C_2-8 alkanoyl, C_1-6 alkyl, and halo C_1-6 alkyl, or R₁ and R₂ together with the carbon atom to which they are attached form carbonyl, thiocarbonyl,

and R₆, R₇, R₈ and Rg are independently hydrogen, C_1-6 alkyl; or substituted and unsubstituted phenyl, or substituted or unsubstituted phenyl C_1-6 alkyl wherein the substituents comprise one to four of one or more groups selected from halogen, nitro, -NR₄R₅, C_2-8 alkanoyl, C_1-6 alkyl, and halo C_1-6 alkyl; or substituted or unsubstituted heterocyclyl, said heterocyclyl being a five- or six-membered ring system containing carbon and one to four heteroatoms selected from one or more of N, O, and S, said heterocyclyl substituent being halogen, C_1-6 alkyl, C_2-8 alkanoyl, or substituted and unsubstituted phenyl, or substituted or unsubstituted phenyl C_1-6 alkyl wherein the substituents comprise one to four of one or more groups selected from halogen, nitro, ―NR₄R₅; C_2-8 alkanoyl, C_1-6 alkyl, and halo C_1-6 alkyl;

R₄ and R₅ are independently hydrogen, C_1-6 alkyl, N,N-di-C_1-6 alkylcarbamoyl, N,N-di-C_1-6 alkylthiocarbamoyl, carbonyl bounded to substituted or unsubstituted phenyl or substituted or unsubstituted phenyl C_1-6 alkyl wherein the substituents comprise one to four of one or more groups selected from halogen, nitro, ―NR₄R_5, C_2-8 alkanoyl, C_1-6 alkyl, and halo C_1-6 alkyl, or substituted or unsubstituted phenyl, or substituted or unsubstituted phenyl C_1-6 alkyl wherein the substituents comprise one to four of one or more groups selected from halogen, nitro, ―NR₄R_5, C_2-8 alkanoyl, C_1-6 alkyl, and halo C_1-6 alkyl, or R₄ and R₅ taken together with the nitrogen atom to which they are attached in ―NR₄R₅ and ―CH₂NR₄R₅ form substituted or unsubstituted heterocyclyl as defined above;

Z is O, S or NR₅ where where R₅ is as defined previously;

n = 1 or 2; and

m = ₁, ₂, ₃or₄.

2. A compound of claim 1 wherein one of R₁ and R₂ is hydrogen and the other is hydroxyl.

3. A compound of claim 1 or 2 wherein n is 1.

4. A compound of any one of claims 1 to 3 wherein Y is imidazolyl.

5. A compound of any one of claims 1 to 4 wherein R₃ is

and R₇, R₈ and R₉ are as previously defined.

6. A compound of claim 1 which is 2-allyl-6-chloro-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)benzo[b]thiophene.

7. A compound of claim 6 wherein the 3-hydroxy and 2-(1 H-1-imidazolylmethyl) groups are cis to each other.

8. A compound of claim 6 wherein the 3-hydroxy and 2-(1H-1-imidazolylmethyl) groups are trans to each other.

9. A compound of claim 1 which is 2-allyl-6-chloro-2,3-dihydro-3-fluoro-2-(1H-1-imidazolylmethyl)benzo[b]thiophene, or

2-allyl-3-(2-chloro-6-fluorobenzyloxy)-2,3-dihydro-6-fluoro-2-(1H-1-imidazolylmethyl)-benzo[b]thiophene, or

2-allyl-3-(2,6-difluorobenzyloxy)-2,3-dihydro-6-fluoro-2-(1H-1-imidazolylmethyl)benzo[b]thiophene, or

2-allyl-2,3-dihydro-6-chloro-2-(1H-1-imidazolylmethyl)benzo[b]thiophene, or

2-allyl-2,3-dihydro-5-fluoro-3-hydroxy-2-(1,2,4-triazol-1-ylmethyl)benzo[b]thiophene, or

6-chloro-2,3-dihydro-3-hydroxy-2-(1H-1-imidazolylmethyl)-2-[2-(4-chlorophenyl)-2-propenyl]-benzo[b]thiophene, or

6-chloro-2,3-dihydro-3-(1H-1-imidazolyl)-2-(1H-imidazol-1-ylmethyl)-2-allyl-benzo[b]thiophene.

10. A pharmaceutical composition comprising an antifungally effective amount of a compound of any one of claims 1 to 9 and a pharmaceutically acceptable carrier.

11. The use of a compound as defined in any one of claims 1 to 9 for the preparation of a pharmaceutical composition useful for treating fungal infections.

12. A method for making a pharmaceutical composition comprising mixing a compound of formula I as defined by any one of claims 1 to 9 with a pharmaceutically acceptable carrier.

13. A process for producing a compound of formula I as defined by claim 1 characterized in that:

to produce a compound of formula I wherein R₁ and R₂, together with the carbon atom to which they are attached, form a carbonyl group and R₃ is

heating a compound of formula V in solvent

to form a compound of formula la

wherein R₇, R₈, R₉, X, Y, n and m are as previously defined,

followed if desired by one or more of sub-processes (i) to (xiii) listed below:

(i) to produce a compound of formula I wherein R₁ and R₂, together with the carbon atom to which they are attached, form the group

reacting a compound having the formula

with a compound having the formula

to form a compound having the formula

wherein L, and L₂ are lower alkyl and R₃, R_s, X, Y, Z, m and n are as previously defined;

(ii) to produce a compound of formula I wherein R₁ and R₂, together with the carbon atom to which they are attached form the group

reacting a compound having the formula

with a compound of the formula

to form a compound of the formula

wherein R₃, R₄, X, Y, m, and n are as previously defined;

(iii) To produce a compound of formula I wherein R, and R₂, together with the carbon atom to which they are attached, form a thiocarbonyl group, reacting a compound of the formula

with a sulfur-introducing reagent to form a compound having the formula

wherein R₃, X, Y, m, and n are as previously defined

(iv) to form a compound of formula I wherein one of R₁ is hydrogen and the other is hydroxyl, reducing a compound of the following formula with a metal boro hydride or aluminum hydride

to form a compound having the formula

wherein R_3, X, Y, m, and n are as previously defined;

(v) to produce a compound of formula I wherein one of R₁ and R₂is hydrogen, and the other is-NR₄R₅, -OR₄, or ―SR_5, reacting a compound having the formula

wherein R_2' is ―OH, ―SH, or ―NH_2, with a compound of the formula

to form a compound of the formula

wherein R₂" is -NR₄R₅, -OR₄, or ―SR_5, L₃ is a leaving group and R₃, X, Y, m, and n are as previously defined;

(vi) To make a compound of formula I wherein R₃ is

catalytically hydrogenating a compound of formula Ij

to form a compound having the formula:

wherein R_{1, R2}, R_{7, R8}, R_{9, X}, _Y, _m, and n are as previously defined;

(vii) To produce a compound of formula I wherein R₃ is ―CHR₇―C≡CR_8, halogenating a compound of the formula

wherein R_1, R₂, R_7, R_8, X, Y, m, and n are as previously defined, and reacting the so-obtained compound with potassium or sodium hydroxide followed by reaction with potassium or sodium amide;

(viii) to produce a compound of formula I wherein one of R₁ and R₂ is halogen, reacting a compound of the following formula

with a compound that replaces hydroxy by halogen to form a compound of the formula

wherein Hal represents halogen and R_i, R₃, X, Y, m, and n are as previously defined;

(ix) to produce a compound of formula I wherein both R₁ and R₂ are hydrogen, reacting a compound of the following formula

with a halogen displacement agent to form a compound of the formula

wherein Hal is halogen and R₃, X, Y, m, and n are as previously defined;

(x) to produce a compound wherein one of R₁ and R₂ is substituted or unsubstituted heterocyclyl, said substituents being as previously defined, reacting a compound of the formula

with a compound of the formula

to form a compound of the formula

wherein Het is substituted or unsubstituted heterocyclyl and Hal is halogen, and R_1, R₃, X, Y, m, and n are as previously defined;

(xi) To produce a compound of formula I wherein one of R₁ or R₂ is C_1-6 alkyl or C_2-8 alkynyl, and the other is hydroxyl, reacting a compound of the formula

with a compound that introduces hydrogen and a C_1-6 alkyl or C₂-₈ alkynyl group, to form a compound having the formula

wherein Alk is C_1-6 alkyl or C_2-8 alkynyl and R₃, X, Y, m, and n are as defined previously;

(xii) separating a mixture of optical isomers; and/or

(xiii) converting the so obtained compound to a pharmaceutically acceptable salt.